Xencor, Inc. (NASDAQ:XNCR)
| Market Cap | $2.66B+160.2% |
| Revenue (ttm) | $200.49M+19.8% |
| Net Income | -$117.86M+15.1% |
| EPS | -$1.59+15.4% |
| Shares Out | 74.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,115,911 |
| Open | $34.21 |
| Previous Close | $34.05 |
| Day's Range | $34.02 - $36.47 |
| 52-Week Range | $10.38 - $36.50 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | $43.86(+22.69%) |
| Earnings Date | Feb 24, 2027 |
About XNCR
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 24, 2027Earnings report
$XNCR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in XNCR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by XNCR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
XNCR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
XNCR Revenue by Segment or Geography
| Royalties | $87.52M | 75.11% |
| Milestone | $29.00M | 24.89% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New XNCR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to XNCR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in XNCR
| IJRiShares Core S&P Small-Cap ETF | $141.24M |
| IWMiShares Russell 2000 ETF | $62.40M |
| VTIVanguard Morningstar Total Stock Market ETF | $58.73M |
| XBIState Street SPDR S&P Biotech ETF | $45.94M |
| IWNiShares Russell 2000 Value ETF | $22.56M |
| SPSMState Street SPDR Portfolio S&P 600 Small Cap ETF | $21.60M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from XNCR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong positive catalyst from Phase 3 kidney cancer trial data with impressive response rates; analyst upgrade significantly raised price target from $20 to $43.